tirzepatide and osteoporosis Association of use with risk of compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database Effects of Semaglutide and Tirzepatide

In contrast, those who switched to placebo regained a significant amount of weight, increasing by 14% on average during that period

Zepbound (tirzepatide) is a GIP and GLP-1 agonist that works in the treatment of people with obesity or with excess weight and weight-related medical problems by activating the receptors for the natural incretin hormones GIP and GLP-1 to decrease food intake and slow gastric emptying

At sub-therapeutic levels like 0.5 mg (10 units from a 5 mg/mL vial), receptor activation is minimal

The Ser8 and Ser11 of Tirzepatide form a network of hydrogen bonds involving the receptor residue Thr298

What happens when you stop taking tirzepatide This section matters more than any other in this guide